Market Risers: Agronomics Ltd, Applied Graphene Materials, AstraZeneca, Avacta Group

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

The stock price for Agronomics Ltd ticker lookup code: LON:ANIC has climbed 4% or 0.2 points during today’s session so far. Buyers have remained optimistic during this period. The periods high figure was 5.2 and a low of 5.1. The total volume of shares traded by this point was 5,753 with the daily average at 1,067,470. The 52 week high is 12.5 amounting to 7.5 points difference from the previous days close and putting the 52 week low at 4.25 which is a difference of 0.75 points. Agronomics Ltd has a 20 day moving average of 5.39 and now a 50 day simple moving average now at 6.39. The market cap now stands at £17.24m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Agronomics Ltd being recorded at Friday, July 17, 2020 at 11:00:03 AM GMT with the stock price trading at 5.2 GBX.

The trading price for Applied Graphene Materials with EPIC code: LON:AGM has risen 6.51% or 1.4 points during today’s session so far. Market buyers have so far held a positive outlook while the stock has been in play. The period high was 23 dropping as low as 20. Volume total for shares traded during this period was 23,206 with the daily average at 198,576. A 52 week share price high is 34.88 amounting to 13.38 points difference from the previous days close and putting the 52 week low at 7 making a difference of 14.5 points. Applied Graphene Materials now has a 20 moving average of 20.22 and the 50 day MA at 15.96. This puts the market cap at £11.32m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for Applied Graphene Materials being recorded at Friday, July 17, 2020 at 11:28:50 AM GMT with the stock price trading at 22.9 GBX.

The stock price for AstraZeneca with ticker code: LON:AZN has climbed 2.38% or 210.6 points during the course of today’s session so far. Investors have remained positive during this period. The period high was 9079 meanwhile the session low reached 8920. The volume total for shares traded up to this point was 910,362 with the daily average at 2,240,810. The 52 week high is 9335 which comes in at 491 points difference from the previous days close and putting the 52 week low at 5871 which is a difference of 2973 points. AstraZeneca now has a 20 simple moving average of 8637.69 and a 50 day MA at 8730.29. This puts the market cap at £118,786.78m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Friday, July 17, 2020 at 12:27:23 PM GMT with the stock price trading at 9054.6 GBX.

Shares in Avacta Group with company EPIC: LON:AVCT has moved up 10.55% or 12.5 points throughout the session so far. Traders are a positive bunch throughout the trading session. The high for the period has peaked at 132.98 while the low for the session was 116.04. The total volume of shares exchanged through this period comes to 1,423,713 with the average number of shares traded daily being 6,129,596. The 52 week high for the shares is 215.25 which comes in at 96.75 points difference from the previous days close and putting the 52 week low at 13 which is a difference of 105.5 points. Avacta Group has a 20 day moving average of 131.19 and also a 50 day moving average now at 146.97. The market capitalisation is now £326.39m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Avacta Group being recorded at Friday, July 17, 2020 at 12:24:48 PM GMT with the stock price trading at 131 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

Search

Search